Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiidi ained, välja arvatud kortikosteroidid - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Eesti - eesti - Ravimiamet

sanofi winthrop industrie - ramipriil+hüdroklorotiasiid - tablett - 5mg+25mg 28tk; 5mg+25mg 56tk; 5mg+25mg 14tk; 5mg+25mg 300tk; 5mg+25mg 30tk; 5mg+25mg 98tk; 5mg+25mg 99tk; 5mg+25mg 50tk

Eesti - eesti - Ravimiamet

sanofi winthrop industrie - ramipriil - tablett - 5mg 50tk; 5mg 18tk; 5mg 45tk; 5mg 300tk; 5mg 14tk; 5mg 90tk; 5mg 98tk; 5mg 99tk; 5mg 10tk; 5mg 15tk; 5mg 30tk; 5mg 100tk

Eesti - eesti - Ravimiamet

sanofi winthrop industrie - ramipriil+hüdroklorotiasiid - tablett - 10mg+12,5mg 30tk; 10mg+12,5mg 28tk; 10mg+12,5mg 60tk; 10mg+12,5mg 56tk; 10mg+12,5mg 100tk; 10mg+12,5mg 10tk

Eesti - eesti - Ravimiamet

sanofi pasteur - marutõve koguviirus, inaktiveeritud - süstesuspensiooni pulber ja lahusti - 1annus 10tk; 1annus 1tk; 1annus 5tk

Eesti - eesti - Ravimiamet

sanofi winthrop industrie - ramipriil - tablett - 2,5mg 20tk; 2,5mg 98tk; 2,5mg 10tk; 2,5mg 300tk; 2,5mg 18tk; 2,5mg 28tk; 2,5mg 90tk; 2,5mg 100tk; 2,5mg 15tk; 2,5mg 30tk; 2,5mg 500tk; 2,5mg 50tk; 2,5mg 60tk

Eesti - eesti - Ravimiamet

sanofi-aventis groupe - ramipriil+hüdroklorotiasiid - tablett - 2,5mg+12,5mg 99tk; 2,5mg+12,5mg 50tk; 2,5mg+12,5mg 14tk; 2,5mg+12,5mg 100tk; 2,5mg+12,5mg 45tk; 2,5mg+12,5mg 20tk; 2,5mg+12,5mg 18tk; 2,5mg+12,5mg 60tk; 2,5mg+12,5mg 98tk; 2,5mg+12,5mg 10tk

Eesti - eesti - Ravimiamet

sanofi winthrop industrie - levofloksatsiin - õhukese polümeerikattega tablett - 500mg 14tk; 500mg 10tk; 500mg 500tk; 500mg 5tk; 500mg 1tk; 500mg 50tk; 500mg 200tk; 500mg 7tk

Eesti - eesti - Ravimiamet

sanofi-aventis estonia oÜ - glimepiriid - tablett - 6mg 30tk; 6mg 28tk; 6mg 60tk; 6mg 50tk; 6mg 90tk; 6mg 112tk; 6mg 120tk

Eesti - eesti - Ravimiamet

sanofi winthrop industrie - glimepiriid - tablett - 1mg 30tk; 1mg 120tk; 1mg 112tk; 1mg 14tk; 1mg 300tk; 1mg 15tk; 1mg 50tk; 1mg 20tk; 1mg 90tk; 1mg 60tk